NNVC Keeping it real board for pro and con discussions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC Keeping it real board for pro and con discussions

NNVC 1.215

-2.8%

Nov 28 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Rawnoc	12/28/2014 10:19:47 PM
	of 326

FLUDASE: (1) Proof mouse studies showed as much as an over 10,000 fold reduction in viral load: "The plaque purified R292K virus variants of Shanghai/1 and Taiwan/1 H7N9 viruses exhibited highly reduced inhibition by oseltamivir carboxylate (>10000-fold)" jid.oxfordjournals.org (2) Proof the Phase 2 trial was indeed a success: "DAS181 significantly reduced viral load in participants infected with influenza, thus warranting future clinical development of this novel host-directed therapy." jid.oxfordjournals.org (3) Proof there were no serious side effedts: "DAS181 was found to be well tolerated in all treatment groups, and no serious adverse events were observed." jid.oxfordjournals.org (4) Proof the Phase 2 trials weren't even for "observated" clinical effects: A lack of observed clinical effects despite the decreased viral load is something that should concern NNVC investors as well as its very existence depends on viral load reduction theory. Also, you "forgot" to mention this: "There are a number of possible reasons for the lack of observed clinical effects in this study. This study was not designed, nor sufficiently powered, to assess clinical efficacy of DAS181 on influenza symptoms. Symptom scores were collected only once daily on days 1, 2, 3, 5, 8, and 14. This is in contrast with pivotal studies for oseltamivir and zanamivir, in which clinical assessments were collected twice daily [16]. Hence, more subtle differences in clinical outcomes (especially if less than 24–36 hours) may not have been detected." (5) Proof Ansun Biopharmaceuticals now owns NexBio but is still quite actively pursuing Fludase as an FDA approved and commercially available influenza drug: ansunbiopharma.com (6) Proof Ansun is recently and continually engaging in human trials as I type to you: This study is currently recruiting participants Estimated Enrollment: 93 Study Start Date: March 2014 Estimated Study Completion Date: April 2015 Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure) clinicaltrials.gov Estimated Enrollment: 60 Study Start Date: August 2013 Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure) clinicaltrials.gov Phase 3 on deck. How's NNVC's two-week long laughable trials going?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next